Colorectal Cancer Biomarkers
Key Points
Key Points
Current evidence-based recommendations for the molecular testing of CRC tissues to guide EGFR-targeted therapies and conventional chemotherapy regimens were developed through collaboration of four societies: American Society for Clinical Pathology (ASCP), College of American Pathologists (CAP), Association for Molecular Pathology (AMP), and American Society of Clinical Oncology (ASCO).
Diagnosis
Diagnosis
...l carcinoma patients being considered for...
....V600 (BRAF c. 1799 (p.V600) mutational an...
...0 mutational analysis should be performed in...
...ould order mismatch repair status testing in pati...
...cient evidence to recommend BRAF c.1799 p.V6...
...ficient evidence to recommend PIK3C...
...is insufficient evidence to recommend PTEN an...
...ecurrent colorectal carcinoma tissues a...
...ixed paraffin embedded tissue is an accep...
...tories must use validated colorectal...
...molecular biomarker testing for colorectal...
...boratories must validate the perform...
Laboratories must provide clinically a...
...IHC biomarker testing in colorectal...
...should establish policies to ensure ef...
...he patient’s medical team, including pathologist...
...aboratories that require send out of tests for...
...athologists must evaluate candidat...
...ould use colorectal carcinoma molecular biomarke...
...rcinoma molecular biomarker results should be ma...
...al carcinoma molecular biomarker testing re...
...es must incorporate colorectal carci...
...1. Outcomes of RAS Mutations and Anti-EGFR...
...ance Rates Between Primary and Metastatic Le...